Myths & Misconceptions of Biotech Securities Claims: An Analysis of...


There is a common life cycle for Directors and Officers Liability for a publicly-traded biotechnology company bringing its first drug or device to the market. In the early stages, whether pre-clinical or Phase 1, there is more than adequate capacity in the marketplace and coverage can be attained rather competitively.



from Biotech News